VisusNano awarded over £225,000 by Innovate UK
VisusNano, a medtech company developing a biodegradable intraocular lens that can release drugs directly into the eye, has been awarded just over £225,000 by Innovate UK. VisusNano was awarded the funding for its drug-eluting MEDILens product, which is being developed to release anti-inflammatory drugs directly into the patients’ eye following cataract surgery.
VisusNano opens new facility at Discovery Park
Medtech company VisusNano announces the opening of its 800 sq. ft facility at Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing companies. The expansion will enable the rapid scale up of the company’s proprietary biodegradable intraocular lens, known as MEDILens. The drug-eluting lens is being developed to release anti-inflammatory drugs directly into the patients’ eye following cataract surgery.
Start-up receives Innovate UK funding for intraocular lens implant
Medtech start-up VisusNano has been awarded £1.39m from the Innovate UK’s Biomedical Catalyst programme to further develop VisiLens, a drug-eluting intraocular lens implant (IOL) for patients undergoing cataract surgery. The funding will allow the company to test the implant’s safety and efficacy humans, the next step getting the product to market.
Innovate UK awards £1.39m for implant used in cataract surgery
VisusNano has been awarded £1.39 million in non-dilutive funding from the Innovate UK Biomedical Catalyst programme to further develop VisILens, a drug-eluting intraocular lens implant (IOL), for use in patients undergoing cataract surgery.